Search hospitals

>

Ohio

>

Columbus

Arthur G. James Cancer Hospital - Ohio State University

Claim this profile

Columbus, Ohio 43202

Global Leader in Lymphoma

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Leukemia

Conducts research for Acute Myelogenous Leukemia

491 reported clinical trials

16 medical researchers

Photo of Arthur G. James Cancer Hospital - Ohio State University in ColumbusPhoto of Arthur G. James Cancer Hospital - Ohio State University in ColumbusPhoto of Arthur G. James Cancer Hospital - Ohio State University in Columbus

Summary

Arthur G. James Cancer Hospital - Ohio State University is a medical facility located in Columbus, Ohio. This center is recognized for care of Lymphoma, Lung Cancer, Breast Cancer, Leukemia, Acute Myelogenous Leukemia and other specialties. Arthur G. James Cancer Hospital - Ohio State University is involved with conducting 491 clinical trials across 358 conditions. There are 16 research doctors associated with this hospital, such as Uma Borate, MD, Alice Mims, Sagar Sardesai, MD, and David O'Malley, MD.

Area of expertise

1

Lymphoma

Global Leader

Arthur G. James Cancer Hospital - Ohio State University has run 61 trials for Lymphoma. Some of their research focus areas include:

Stage IV
Stage III
CCND1 positive
2

Lung Cancer

Global Leader

Arthur G. James Cancer Hospital - Ohio State University has run 52 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRAF positive

Top PIs

Clinical Trials running at Arthur G. James Cancer Hospital - Ohio State University

Myelofibrosis

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Lung Cancer

Multiple Myeloma

Acute Myelogenous Leukemia

Follicular Lymphoma

Mantle Cell Lymphoma

Myelodysplastic Syndrome

Leukemia

Image of trial facility.

Bomedemstat

for Blood Disorders

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Pacritinib

for Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Arthur G. James Cancer Hospital - Ohio State University?

Where is Arthur G. James Cancer Hospital - Ohio State University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Arthur G. James Cancer Hospital - Ohio State University accept?

What awards or recognition has Arthur G. James Cancer Hospital - Ohio State University received?